Lung disease due to the more common nontuberculous mycobacteria

Chest

Volumn 129, Issue 6, 2006, Pages 1653-1672

  Field, Stephen K ^a,b   Cowie, Robert L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Health Science Centre   (Canada)

Author keywords

Environmental mycobacteria; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium fortuitum; Mycobacterium gordonae; Mycobacterium kansasii; Mycobacterium malmoense; Mycobacterium xenopi; Nontuberculous mycobacteria; Tuberculosis

Indexed keywords

AMIKACIN; AZITHROMYCIN; BCG VACCINE; CD4 ANTIGEN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DOXYCYCLINE; ETANERCEPT; ETHAMBUTOL; GAMMA INTERFERON; IMIPENEM; INFLIXIMAB; ISONIAZID; MACROLIDE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

AIDS PATIENT; ALLERGIC PNEUMONITIS; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BCG VACCINATION; BRONCHIECTASIS; BRONCHOSCOPY; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DNA PROBE; FUNNEL CHEST; GRANULOMATOUS INFLAMMATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMA CAPSULATUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; LADY WINDERMERE SYNDROME; LISTERIA MONOCYTOGENES; LUNG DISEASE; LUNG FUNCTION; LUNG SARCOIDOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM HAEMOPHILUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM SCROFULACEUM; MYCOBACTERIUM XENOPEI; NUCLEIC ACID AMPLIFICATION; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PNEUMOCYSTIS JIROVECI; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SCOLIOSIS; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; THORAX WALL DEFECT; TUBERCULOSIS;

EID: 33745131823     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1653     Document Type: Article

References (277)

1. Huard RC, Lazzarini LC, Butler WR, et al. PCR based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol 2003; 41:1637-1650
2. Herdman AV, Steele JC Jr. The new mycobacterial species-emerging or newly distinguished pathogens. Clin Lab Med 2004; 24:651-690
3. Mostowy S, Behr MA. The origin and evolution of Mycobacterium tuberculosis. Clin Chest Med 2005; 26:207-216
4. Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177-215
5. Falkinham JO III. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23:529-551
6. Primm TP, Lucero CA, Falkinham JO III. Health impacts of environmental mycobacteria. Clin Microbiol Rev 2004; 17:98-106
7. Thomsen VO, Andersen AB, Miorner H. Incidence and clinical significance of non-tuberculous mycobacteria isolated from clinical specimens during a 2-y nationwide survey. Scand J Infect Dis 2002; 34:648-653
8. Haverkort F. National atypical mycobacteria survey, 2000. Commun Dis Intel 2003; 27:180-189
9. Butler WR, Crawford JT. NTM reported to the public health laboratory information system by state public health laboratories United States 1993-1996, July 1999. Available at: www. cdc.gov/ncidod/dastlr/mycobacteriology.htm. Accessed July 1, 2005
10. Martin-Casabona N, Bahrmand AR, Bennedsen J, et al. Non-tuberculous mycobacteria: patterns of isolation: a multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8:1186-1193
11. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25
12. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55:210-218
13. Holland SM. Nontuberculous mycobacteria. Am J Med Sci 2001; 321:49-55
14. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941-1949
15. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-1961
16. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364-2369
17. Holland SM. Immune deficiency presenting as mycobacterial infection. Clin Rev Immunol 2001; 20:121-137
18. Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytolane Growth Factor Rev 2000; 11:321-333
19. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21:370-378
20. Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47-59
21. Shirasuchi H, Ellner JJ. Expression of IL-18 by Mycobacterium nuium-infected human monocytes: association with M amum virulence. Clin Exp Immunol 2001; 123:203-209
22. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160:5428-435
23. Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-γ, interleukin-12, and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency. J Infect Dis 1998; 178:1095-1104
24. Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293:300-303
25. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107-159
26. Lewis AG Jr, Dunbar FP, Lasche EM, et al. Chronic pulmonary disease due to atypical mycobacterial infections. Am Rev Respir Dis 1959; 80:188-199
27. Reznikov M, Leggo JH. Investigation by seroagglutination of strains of the Mycobacterium intracellulare-M scrofulaceum group from house dusts and sputum in southeastern Queensland. Am Rev Respir Dis 1971; 104:951-953
28. Bhatia SVN. A study of mycobacterial species isolated from patients with chronic respiratory disease. Am Rev Respir Dis 1973; 108:378-381
29. Robakiewicz M, Grzybowski S. Epidemiologic aspects of nontuberculous mycobacterial disease and of tuberculosis in British Columbia. Am Rev Respir Dis 1974; 109:613-620
30. Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis 1976; 113:287-292
31. Meissner G, Anz W. Sources of Mycobacterium avium complex resulting in human diseases. Am Rev Respir Dis 1977; 116:1057-1064
32. Schaeffer WB. Incidence of the serotypes of Mycobacterium avium and atypical mycobacteria in human and animal diseases. Am Rev Respir Dis 1968; 97:18-23
33. Sriyabhaya N, Wongwatana S. Pulmonary infection caused by atypical mycobacteria in Thailand. Rev Infect Dis 1981; 3:1085-1089
34. Kleeberg HH. Epidemiology of mycobacteria other than tubercle bacilli in South Africa. Rev Infect Dis 1981; 3:1008-1012
35. Gorse GJ, Fairshter RD, Friedly G, et al. Nontuberculous mycobacterial disease: experience in a Southern California hospital. Arch Intern Med 1983; 143:225-228
36. Miguez-Burbano MJ, Shor-Posner G, Hadrigan S. Non-tuberculous mycobacteria in HIV-infectecl patients: geographic, behavioural, and immunologic factors. Lancet Infect Dis 2005; 5:394-395
37. Reich J, Field SK, Fisher D, et al. Treatment outcome in Mycobacterium avium pulmonary disease: a correction and comment. Chest 2005; 127:1864-1866
38. Donnabella V, Salazas-Schicchi J, Bonk S, et al. Increasing incidence of Mycobacterium xenopi at Bellevue hospital: an emerging pathogen or a product of improved laboratory methods? Chest 2000; 118; 1365-1370
39. Crow HE, King CT, Smith CE, et al. A limited clinical, pathologic, and epidemiologic study of patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum. Am Rev Respir Dis 1957; 75:199-222
40. Phillips S, Larkin JC Jr. Atypical pulmonary tuberculosis caused by unclassified mycobacteria. Ann Intern Med 1964; 60:401-488
41. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial disease in the United States: results from a national survey. Am Rev Respir Dis 1987; 135:1007-1014
42. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863-868
43. Cox JN, Brenner ER, Bryan CS. Changing patterns of mycobacterial disease at a teaching community hospital. Infect Control Hosp Epidemiol 1994; 15:513-515
44. Elwood RK, Opazo AM, Lentini V, et al. Incidence of pulmonary disease caused by mycobacteria other than tuberculosis in British Columbia. Can Respir J 2002; 9:319-323
45. Kennedy MP, O'Connor TM, Ryan C, et al. Nontuberculous mycobacteria: incidence in Southwest Ireland from 1987 to 2000. Respir Med 2003; 97:257-263
46. Matsos ED, Santana MA, de Santana MC, et al. Nontuberculous mycobacteria at a multiresistant tuberculosis reference center in Bahia: clinical epidemiologic aspects. Braz J Infect Dis 2004; 8:296-304
47. Henry MT, Inamdar L, O'Riordan, et al. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment, and response. Eur Respir J 2004; 23:741-746
48. Morita H, Usami I, Torii M, et al. Isolation of non-tuberculous mycobacteria from patients with pneumoconiosis. J Infect Chemother 2005; 11:89-92
49. Fujita J, Kishimoto T, Ohtsuki Y, et al. Clinical features of eleven cases of Mycobacterium avium-intracellulare complex pulmonary disease associated with pneumoconiosis. Respir Med 2004; 98:721-725
50. Kilby JM, Gilligan PH, Yankaskas JR, et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102:70-75
51. Barker AF. Bronchiectasis. N Engl J Med 2002; 346:1383-1393
52. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination: 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuberc Lung Dis 1994; 75:348-352
53. Romanus V, Hallander HO, Wahlen P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuberc Lung Dis 1995; 76:300-310
54. O'Brien DP, Currie BJ, Krause VL, et al. Nontuberculous mycobacterial disease in Northern Australia: a case series and review of die literature. Clin Infect Dis 2000; 31:958-968
55. Parker BC, Ford MA, Gruft H, et al. Epidemiology of infection by nontuberculous mycobacteria: IV. Preferential aerosolization of Mycobacterium intracellulare from natural waters. Am Rev Respir Dis 1983; 128:652-656
56. Christensen EE, Dietz GW, Aim CH, et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections. Chest 1981; 80:132-136
57. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: clinical features and course in 100 consecutive cases. Chest 1979; 75:115-960
58. Christensen EE, Dietz GW, Ahn CH, et al. Pulmonary manifestations of Mycobacterium intracellularis. AJR Am J Roentgenol 1979; 133:59-66
59. Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Ann Rev Respir Dis 1982; 125:388-391
60. Field SK, Cowie RL. Treatment of Mycobacterium avium complex (MAC) lung disease in non-HIV infected patients. Chest 2003; 124:1482-1486
61. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005; 60:1048-1051
62. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: die Lady Windermere syndrome. Chest 1992; 101:1605-1609
63. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000; 30:572-575
64. Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 2002; 23:623-632
65. Embril J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water: hypersensitivity pneumonitis or infection? Chest 1997; 111:813-816
66. Case records of the Massachusetts General Hospital: case 27-2000. N Engl J Med 2000; 343:642-649
67. Kahana LM, Kay JM, Yakrus MA, et al. Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest 1997; 111:242-245
68. Cappelluti E, Fraire AE, Schaefer OP. A case of "hot tub lung" due to Mycobacterium avium complex in an immunocompetent host. Arch Intern Med 2003; 163:845-848
69. Khoor A, Leslie KO, Tazelaar HD, et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001; 115:755-762
70. Rickman OB, Ryu JH, Fidler ME, et al. Hypersensitivity pneumonitis associated with Mycobacterium avium complex and hot tub use. Mayo Clin Proc 2002; 77:1233-1237
71. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect 2003; 18:33-39
72. Systrom DM, Wittram C. Case 9-2005: a 67-year-old man with acute respiratory failure. N Engl J Med 2005; 352:1238-1246
73. Marras TK, Wallace RJ Jr, Koth LL, et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005; 127:664-671
74. Hanak V, Kalra S, Aksamit TR, et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006; 100:610-615
75. Lumb R, Stapledon R, Scroop A, et al. Investigation of spa pools associated with lung disorders caused by Mycobacterium avium complex in immunocompetent adults. Appl Env Microbiol 2004; 70:4906-4910
76. Falkinham JO. Mycobacterial aerosols and respiratory disease. Emerg Infect Dis 2003; 9:763-767
77. Wilson RW, Steingrube VA, Hottger EC, et al. Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks and contaminated metalworking fluids; an international cooperative study on mycobacterial taxonomy. Int J Syst Evol Microbiol 2001; 51:1751-1764
78. Marchetti N, Criner K, Criner GJ. Characterization of functional, radiologic, and lung function recovery post-treatment of hot tub lung: a case report and review of the literature. Lung 2004; 182:271-277
79. Pinner M. Atypical acid-fast microorganisms. Am Rev Tuberc 1935; 32:424-439
80. Edwards LB, Palmer CE. Isolation of "atypical" mycobacteria from healthy persons. Am Rev Respir Dis 1959; 80:747-749
81. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940-953
82. Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus infection. Am J Respir Crit Care Med 2004; 170:793-798
83. Feldman WH, Davies R, Moses HE, et al. An unusual mycobacterium isolated from sputum of a man suffering from pulmonary disease of long duration. Am Rev Tuberc 1943; 48:82-93
84. Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr 1980; 96:689-691
85. Esther CR Jr, Henry MM, Molina PL, et al. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40:39-44
86. Pierre-Audigier C, Ferroni A, Sermet-Gaudelas I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467-3470
87. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria: I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828-834
88. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171:621-626
89. Mnssaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and systemic steroid therapy. Eur Respir J 2005; 25:324-328
90. Olivier KN, Weber DJ, Lee J-H, et al. Nontuberculous mycobacteria: II. Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167:835-840
91. Angrill J, Agusti C, Torres A. Bronchiectasis. Curr Opin Infect Dis 2001; 14:193-197
92. Kim TS, Koh WJ, Han J, et al. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation. AJR Am J Roentgenol 2005; 184:1247-1252
93. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis: thoracic abnormalities associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991; 144:914-916
94. Guide SV, Holland SM. Host susceptibility factors in mycobacterial infection: genetics and body morphotype. Infect Dis Clin North Am 2002; 16:163-186
95. Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine 1994; 73:103-109
96. Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171:1142-1149
97. Nontuberculous mycobacteria. Am J Transplant 2004; 4(Suppl 10):42-46
98. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428-1439
99. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611-1616
100. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115:741-745
101. Paull DE, Decker GR, Brown RL. Mycobacterium kansasii empyema in a renal transplant recipient case report and review of the literature. Transplantation 2003; 76:270-271
102. Jie T, Matas AJ, Gillingham KG, et al. Mycobacterial infections after kidney transplant. Transplant Proc 2005; 37:937-939
103. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect 2003; 9:518-525
104. Thaunat O, Morelon E, Stern M, et al. Case report: Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolitnus therapy. Transplant Infect Dis 2004; 6:179-182
105. Weinstock DM, Feinstein MB, Sepkowitz KA, et al. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:1015-1021
106. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41:5199-5203
107. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265
108. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-155
109. Ehlers S, Benini J, Kutsch S, et al. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 1999; 67:3571-3579
110. Marie I, Heliot P, Roussel F, et al. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 2005; 44:1201-1202
111. Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:1332-1338
112. Jones D, Havlir DV. Nontuberculous mycobacteria in the HIV infected patient. Clin Chest Med 2002; 23:665-674
113. Gascon P, Sathe SS, Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Am J Med 1993; 94:41-48
114. Hocqueloux L, Lesprit P, Herrmann JL, et al. Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. Chest 1998; 113:542-548
115. Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129:698-704
116. Marras TK, Daley CL. A systematic review of the clinical significance of pulmonary M kansasii isolates in HIV infection. J Acquir Immune Defic Syndr 2004; 36:883-889
117. Smith MB, Molina CP, Schnadig VJ, et al. Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med 2003; 127:554-560
118. Corbett EL, Blumberg L, Churchyard GJ, et al. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 1999; 160:15-21
119. Corbett EL, Churchyard GJ, Clayton T, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners: a case controlled study. Am J Respir Crit Care Med 1999; 159:94-99
120. Corbett EL, Churchyard GJ, Hay M, et al. The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Am J Respir Crit Care Med 1999; 160:10-14
121. Griffith DE. Management of disease due to Mycobacterium kansasii. Clin Chest Med 2002; 23:613-621
122. El-Helou P, Rachlis A, Fong I, et al. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. Clin Infect Dis 1997; 25:206-210
123. Stoll M, Schmidt RE. Adverse events of desirable gain in immunocompetence: the immune restoration inflammatory syndromes. Autoimmun Rev 2004; 3:243-249
124. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406
125. Buckingham SJ, Haddovv LJ, Shaw PJ, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy. Clin Radiol 2004; 59:505-513
126. Shelburne SA III, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81:213-227
127. Lawn SD, Bekker L-G, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373
128. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159-1166
129. Phillips P, Bonner S, Gataric N, et al. Reconstitution syndrome in HIV-infected patients: spectrum of disease and long-tenu follow-up. Clin Infect Dis 2005; 41:1483-1497
130. Woods GL. The mycobacteriology laboratory and new diagnostic techniques. Infect Dis North Am 2002; 16:127-144
131. Morgan MA, Horstmeier CD, DeYoung DR, et al. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18:384-388
132. Roberts GD, Goodman NL, Heifets L, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol 1983; 18:689-696
133. Mijs W, de Haas P, Rossau R, et al. Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. Avium for bird-type isolates and 'M avium subsp. hominissuis' for the human/porcine type of M avium. Int J Syst Evol Microbiol 2002; 52:1505-1528
134. Tenover FC, Crawford JT, Huebner RE, et al. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 31:767-770
135. Lebrun L, Espinasse F, Poveda JD, et al. Evaluation of non-radioactive DNA probes for identification of mycobacteria. J Clin Microbiol 1992; 30:2476-2478
136. Maesala S, Kohno S, Koga H, et al. A clinical comparison between Mycobacterium avium and Mycobacterium intracellulare infections. Chest 1993; 104:1408-1411
137. Beggs ML, Stevanova R, Eisenach KD. Species identification of Mycobacterium avium complex isolates by a variety of molecular techniques. J Clin Microbiol 2000; 38:508-512
138. Han XY, Tarrand JJ, Infante R, et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol 2005; 43:4407-4412
139. Drake TA, Herron RM Jr, Hindler JA, et al. DNA probe reactivity of Mycobacterium avium complex isolates from patients without AIDS. Diagn Microbiol Infect Dis 1988; 11:125-128
140. Kyriakopoulos AM, Tassios PT, Matsiota-Bemard P, et al. Characterization to species level on Mycobacterium avium complex strains form human immunodeficiency virus positive and negative patients. J Clin Microbiol 1997; 35:3001-3003
141. Tanaka D, Niwatsukino H, Oyama T, et al. Progressing features of atypical mycobacterial infection in the lung on conventional and high resolution CT (HRCT) images. Radiat Med 2001; 19:237-245
142. Bartos M, Hlozek P, Svastova P, et al. Identification of members of Mycobacterium avium species by Accu-Probes, serotyping, and single IS900, IS901, IS1245 and IS901-flanking region PCR with internal standards. J Microbiol Methods 2006; 64:333-345
143. Butler WR, Guthertz LS. Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species. Clin Microbiol Rev 2001; 14:704-726
144. Thibert L, Lapierre S. Routine application of high-performance liquid chromatography for identification of mycobacteria. J Clin Microbiol 1993; 31:1759-1763
145. Leite CQJ, da Silva Rocha A, de Andrade Leite SR, et al. A comparison of mycolic acid analysis for nontuberculous rnycobacteria identification by thin-layer chromatography and molecular methods. Microbiol Immunol 2005; 49:5721-5728
146. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes. 2nd ed. Tentative standard M24-T2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000
147. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31:1209-1215
148. Contreras MA, Cheung OT, Sanders DE, et al. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988; 137:149-152
149. Heifets LB. Synergistic effect of rifampin, streptomycin, ethionamide and ethambutol on Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125:43-48
150. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutin plus ethambutol against Mycobacterium avium complex: bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988; 137:711-715
151. von Reyn CF, Jacobs NJ, Arbeit RD, et al. Polyclonal Mycobacterium avium infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of M. avium isolated from the same patient. J Clin Microbiol 1995; 33:1008-1010
152. Bock NN, McGowan JE Jr, Ahn J, et al. Clinical predictors of tuberculosis as a guide for respiratory isolation policy. Am J Respir Crit Care Med 1996; 154:1468-1472
153. Abelda SM, Kern JA, Marinelli DL, et al. Expanding spectrum of pulmonary disease caused by nontuberculous mycobacteria. Radiology 1985; 157:289-296
154. Miller WT. Spectrum of pulmonary nontuberculous mycobacterial infection. Radiology 1994; 191:343-350
155. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-1104
156. Pottumarthy S, Wells VC, Morris AJ. A comparison of seven tests for serological diagnosis of tuberculosis. J Clin Microbiol 2000; 38:2227-2231
157. Scholvink E, Wilkmson KA, Whelan AO, et al. Gamma interferon-based immunodiagnosis of tuberculosis: comparison between whole-blood and enzyme-linked immunospot methods. J Clin Microbiol 2004; 42:829-831
158. Lalvani A, Brookes R, Wilkinson RJ, et al. Human cytolytic and Interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci 1998; 95:270-275
159. du Moulin GC, Stottmeier KD, Pelletier PA, et al. Concentration of Mycobacterium avium by hospital hot water systems JAMA 1988; 260:1599-1601
160. Arnow PM, Bakir M, Thompson K, et al. Endemic contamination of clinical specimens by Mycobacterium gordonae. Clin Infect Dis 2000; 31:472-476
161. Edwards LB, Palmer CE. Isolation of "atypical" mycobacteria from healthy persons. Am Rev Respir Dis 1959; 80:747-749
162. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940-953
163. Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125:388-391
164. Woods GL. The mycobacteriology laboratory and new diagnostic techniques. Infect Dis North Am 2002; 16:127-144
165. Lincoln EM, Gilbert LA. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am Rev Respir Dis 1972; 105:683-714
166. Horsburgh CR. Epidemiology of human disease caused by Mycobacterium avium complex. Can J Infect Dis 1994; 5;5B-9B
167. Hawkins CC, Gold WM, Whimbey E, et al. Mycobacterium avium-complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:184-188
168. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082-1085
169. Goo JM, Im J-G. CT of tuberculosis and nontuberculous mycobacterial infections. Radiol Clin North Am 2002; 40:73-87
170. Erasmus JJ, McAdams HP, Farrell MA, et al. Pulmonary nontuberculous mycobacterial infection: radiologic manifestations. Radiographics 1999; 19:1487-1503
171. Bates JH. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis; clinical characteristics. Am Rev Respir Dis 1967; 96:1151-1156
172. Vankayalapati R, Wizel B, Samten B, et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J Infect Dis 2001; 183:478-484
173. Warring FC Jr. Mycobacteria in a New England hospital: a study of mycobacterial species occurring in the sputum of patients with chronic pulmonary disease. Am Rev Respir Dis 1968; 98:965-977
174. Beck F. Pulmonary disease due to atypical tubercle bacilli. Am Rev Respir Dis 1959; 80:738-743
175. Kubo K, Yamazaki Y, Hachiya T, et al. Mycobacterium avium-intracellulare pulmonary infection in patients without known predisposing pulmonary disease. Lung 1998; 176:381-391
176. Obayashi Y, Fujita J, Suemitsu I, et al. Clinical features of non-tuberculous mycobacterial disease: comparisons between smear-positive and smear-negative cases, and between Mycobactarium avium and Mycobacterium intracellulare. Int J Tuberc Lung Dis 1998; 2:597-602
177. Primack SL, Logan PM, Hartman TE, et al. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194:413-417
178. Lynch DA, Simone PM, Fox MA, et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr 1995; 19:353-360
179. Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49-52
180. Wittram C, Weisbrod GL. Mycobacterium avium complex lung disease in immunocompetent patients: radiography-CT correlation. Br J Radiol 2002; 75:340-344
181. Olivier KN. Nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med 1998; 4:148-153
182. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155:2041-2046
183. Maycher B, O'Connor R, Long R. Computed tomographic abnormalities in Mycobacterium avium complex lung disease include the mosaic pattern of reduced lung attenuation. Can Assoc Radiol J 2000; 51:93-102
184. Kubo K, Yamakazi Y, Masubuchi T, et al. Pulmonary infection with Mycobacterium avium-intracellulare leads to air trapping distal to the small airways. Am J Respir Crit Care Med 1998; 158:979-984
185. Rollings NP, Wells AU, Wilson R, et al. Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol 2002; 12:2211-2217
186. Hazelton TR, Newell JD Jr, Cook JL, et al. CT findings in 14 patients with Mycobacterium chelonae infection. AJR Am J Roentgenol 2000; 175:413-416
187. Han D, Lee KS, Koh W-J, et al. Radiographic and CT findings of nontuberculous mycobacterial pulmonary infection caused by Mycobacterium abscessus. AJR Am J Roentgenol 2003; 181:513-517
188. Koh WJ, Lee KS, Kwon OJ, et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005; 235:282-288
189. Obayashi Y, Fujita J, Suemitsu I, et al. Successive follow-up of chest computed tomography in patients with Mycobacterium avium-intracellulare complex. Respir Med 1999; 93:11-15
190. Davidson PT, Khanijo V, Goble M, et al. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981; 3:1052-1059
191. Ahn CH, Ahn SS, Anderson RA, et al. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986; 134:438-441
192. The Research Committee of the BTS. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6:628-634
193. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-391
194. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin; Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996; 335:377-383
195. Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149:1335-1341
196. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am J Respir Crit Care Med 1996; 153:1766-1772
197. Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996; 23:983-989
198. Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998; 178:121-126
199. Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30:288-292
200. Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32:1547-1553
201. Dautzenberg B, Piperno P, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107:1035-1040
202. Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome: GETIM; Groupe d'Etude et de Traitment des Infections a Mycobacteries. Int J Tuberc Lung Dis 1998; 2:462-470
203. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160:866-872
204. Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999; 115:1033-1040
205. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against M avium complex organisms. Antimicrob Agents Chemother 1991; 35:462-470
206. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126:566-581
207. Bermudez LE, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrobiol Agents Chemother 1991; 35; 2625-2629
208. Gomez-Flores R, Tucker SD, Kansal R, et al. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-intracellulare complex infection induced by IFN-γ; is mediated by TNF-α. J Antimicrobiol Chemother 1997; 39:189-197
209. Safdar A, Armstrong D, Murray HW. A novel defect of interferon-γ secretion in patients with refractory nontuberculous pulmonary mycobacteriosis [letter]. Ann Intern Med 2003; 138:521
210. Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest 2005; 115:2480-2488
211. Wallace RJ Jr, Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158:1235-1244
212. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated infection with Interferon gamma: a preliminary report. N Engl J Med 1994; 330:1348-1355
213. Chatte G, Panteix G, Perrin-Fayolle M, et al. Aerosolized interferon γ for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995; 152:1094-1096
214. Hallstrand TS, Ochs HD, Zhu Q, et al. Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency. Eur Respir J 2004; 24:367-370
215. Corpe RF. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis 1981; 3:1064-1067
216. Moran JF, Alexander LG, Staub EW, et al. Long-term results of pulmonary resection for atypical mycobacterial disease. Ann Thorac Surg 1983; 35:597-604
217. Nelson KG, Griffith DE, Brown BA, et al. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66:325-330
218. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant Mycobacterium tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52:1108-1112
219. Shiriaishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg 2002; 21:314-318
220. Lamden K, Watson JM, Knerer G, et al. Opportunist mycobacteria in England and Wales: 1982 to 1994. Commun Dis Rep CDR Rev 1996; 11:R147-R151
221. Bittner MJ, Horowitz EA, Safranek TJ, et al. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a Midwestern Veterans Affairs hospital. Clin Infect Dis 1996; 22:1109-1110
222. Taillard C, Greub G, Weber R, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss national survey. J Clin Microbiol 2003; 41:1240-1244
223. Santin M, Alcaide F, Benitez MA, et al. Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiol Infect 2004; 132:425-432
224. Safdar A, White DA, Stover D, et al. Profound interferon ad; deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 2002; 113:756-759
225. Arend SM, Gerda de Palou E, de Haas P, et al. Pneumonia caused by Mycobacterium kansasii in a series of patients without recognized immune defect. Clin Microbiol Infect 2004; 10:738-748
226. Sun Z, Zhang Y. Reduced pvrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agent Chemother 1999; 43:537-542
227. Ahn CH, Lowell JR, Ahn SA, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048-1050
228. Jenkins PA, Banks J, Campbell IA, et al. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 1994; 49:442-445
229. Sauret J, Hernandez-Flix S, Castro E, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii; results of 18 vs 12 months' chemotherapy. Tuberc Lung Dis 1995; 76:104-108
230. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37:1178-1182
231. Rodriguez Diaz JC, Lopez M, Ruiz M, et al. In vitro activity of the new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 212:585-588
232. Alcaide F, Calatayud L, Santin M, et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562-4565
233. Research committee of the British Thoracic Society. First randomized trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167-172
234. Buchholz UT, McNeil MM, Keyes LE, et al. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis 1998; 27:551-558
235. Fakih H, Chapalamadugu S, Ricart A, et al. Mycobacterium malmoense bacteremia in two AIDS patients. J Clin Microbiol 1996; 34:731-733
236. Banks J, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium malmoense: a review of treatment and response. Tubercle 1985; 66:197-203
237. Henriques B, Hoffner SE, Petrini B, et al. Infection with Mycobacterium malmoense in Sweden: report of 221 cases. Clin Infect Dis 1994; 18:596-600
238. Enzensberger R, Hunfeld K-P, Krause M, et al. Mycobacterium malmoense infections in immunocompetent patients. Eur J Clin Microbiol Infect Dis 1999; 18:579-581
239. The research committee of the British Thoracic Society. Pulmonary disease caused by M malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardized treatment. Eur Respir J 2003; 21:478-482
240. Evans AJ, Crisp AJ, Colville A, et al. Pulmonary infections caused by Mycobacterium malmoense and Mycobacterium tuberculosis: comparison of radiographic features. AJR Am J Roentgenol 1993; 161:733-737
241. Alberts WM, Chandler KW, Solomon DA, et al. Pulmonary disease caused by Mycobacterium malmoense. Am Rev Respir Dis 1987; 135:1375-1378
242. Kauppinen J, Mantyjarvi R, Katila M-L. Mycobacterium malmoense-specific nested PCR based on a conserved sequence detected in random amplified polymorphic DNA fingerprints. J Clin Microbiol 1999; 37:1454-1458
243. Simor AE, Salit IE, Velland H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis 1984; 129:435-438
244. Jenkins PA, Campbell IA, and Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five-year follow-up of patients receiving standardized treatment. Respir Med 2003; 97:439-440
245. Dailloux M, Albert M, Laurain C, et al. Mycobacterium xenopi and drinking water biofilms. Appl Environ Microbiol 2003; 69:6946-6948
246. Sniadack DH, Ostroff SM, Karlix MA, et al. A nosocomial pseudo-outbreak of Mycobacterium xenopi due to contaminated potable water supply, lessons in prevention. Infect Control Hosp Epidemiol 1993; 14:636-641
247. Research Committee of the British Thoracic Society. First randomized trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167-172
248. Dauendorffer J-N, Laurain C, Weber M, et al. In vitro sensitivity of Mycobacterium xenopi to five antibiotics. Pathol Biol 2002; 50:591-594
249. Lang-Lazdunski L, Offredo C, Le Pimpec-Barthes F, et al. Pulmonary resection for Mycobacterium xenopi pulmonary infection. Ann Thorac Surg 2001; 72:1877-1882
250. Eckburg PB, Buadu EO, Stark P, et al. Clinical and chest radiographie findings among persons with sputum culture positive for Mycobacterium gordonae: a review of 19 cases. Chest 2000; 117:96-102
251. Lalande V, Barbut F, Varnerot A, et al. Pseudo-outbreak of Mycobacterium gordonae associated with water from refrigerated fountains. J Hosp Infect 2001; 48:76-79
252. Fujita J, Nanki N, Negayama K, et al. Nosocomial contamination by Mycobacterium gordonae in hospital water supply and super-oxidized water. J Hosp Infect 2002; 51:65-68
253. Jackson J, Leggett JE, Wilson DA, et al. Mycobacterium gordonae in fiberoptic bronchoscopes. Am J Infect Control 1996; 24:19-23
254. Barber TW, Craven DE, Farber HW. Mycobacterium gordonae: a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection. Chest 1991; 100:716-720
255. Lessnau K-D, Milanese S, Talavera W. Mycobacterium gordonae: a treatable disease in HIV-positive patients. Chest 1993; 104:1779-1785
256. Woods GL, Washington JA II. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 1987; 9:275-294
257. Brown BA, Wallace JR Jr, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992; 36:1987-1990
258. Den Breeder AA, Vervoort G, van Assen S, et al. Disseminated Mycobacterium gordonae infection in a renal transplant recipient. Transpl Infect Dis 2003; 5:151-155
259. Resch B, Eber E, Beitzke A, et al. Pulmonary infection due to Mycobacterium gordonae in an adolescent immunocompetent patient. Respiration 1997; 64:300-303
260. Koizumi T, Yamazaki Y, Kubo K, et al. Pulmonary Mycobacterium gordonae infection treated with clarithromycin. Kekkaku 2000; 75:711-715
261. Stahl DA, Urbance JW. The division between fast- and slow-growing species corresponds to natural relationships among the mycobacteria. J Bacteriol 1990; 172:116-124
262. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716-746
263. Rolston KVI, Jones PG, Fainstein V, et al. Pulmonary disease caused by rapidly growing mycobacteria in patients with cancer. Chest 1985; 87:503-506
264. Hadjiliadis D, Adlakha A, Prakash UBS. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc 1999; 74:45-51
265. Varghese G, Shepherd R, Watt P, et al. Fatal infection with Mycobacterium fortuitum associated with oesophageal achalasia. Thorax 1988; 43:151-152
266. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am Rev Respir Dis 1993; 147:1271-1278
267. Chung MJ, Lee KS, Koh W-J, et al. Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Mycobacterium avium-intracellulare and Mycobacterium abscessus infection. J Korean Med Sci 2005; 20:777-783
268. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.' Antimicrobial Agent Chemother 2003; 47:1958-1962
269. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant Mycobacterium tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52:1108-1112
270. Shiraishi Y, Nakajima Y, Katsuragi N, et al. Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg 2004; 78:399-403
271. Nash KA, Zhang Y, Brown-Elliott BA, et al. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Anrimicrob Chemother 2005; 55:170-177
272. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716-746
273. Wang H-C, Liaw Y-S, Yang P-C, et al. A pseudoepidemic of Mycobacterium chelonae infection caused by contamination of a fiberoptic bronchoscope suction canal. Eur Respir J 1995; 8:1259-1262
274. Kressel AB, Kidd F. Pseudo-outbreak of Mycobacterium chelonae and Methylobacterium mesophilicum caused by contamination of an endoscopy washer. Infect Control Hosp Epidemiol 2001; 22:414-418
275. Cox R, deBorja K, Bach MC. A pseudo-outbreak of Mycobacterium chelonae infections related to bronchoscopy. Infect Control Hosp Epidemiol 1997; 18:136-137
276. Nomura K, Ogawa M, Miyamoto H, et al. Antibiotic susceptibility of glutaraldehyde-tolerant Mycobacterium chelonae from bronchoscope washing machines. Am J Infect Control 2004; 32:185-188
277. Mehta AC, Prakash UBS, Garland F, et al. American College of Chest Physicians and American Association for Bronchology consensus statement: prevention of flexible bronchoscopy-associated infection. Chest 2005; 128:1742-1755